Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers.
Hepatocyte growth factor (HGF)/c-Met expression is known to be correlated with poor prognosis in several cancers. We investigated HGF/c-Met immunoreactivity and its correlation with clinical features in 51 patients with curatively resected extrahepatic biliary tract carcinoma. c-Met showed significant correlations with tumor location, T category, stage, perineural invasion and local recurrence. Overall survival in patients with HGF and c-Met immunopositivity was significantly worse than in those who were negative. Our findings suggest that HGF/c-Met play some roles in tumor development and that HGF/c-Met immunoreactivity could be a predictor of the mode of recurrence and poor prognosis.
Hida
Y
Y
Second Department of Surgery, School of Medicine, Hokkaido University, Kita-Ku, Sapporo 060-8638, Japan.
Morita
T
T
Fujita
M
M
Miyasaka
Y
Y
Horita
S
S
Fujioka
Y
Y
Nagashima
K
K
Katoh
H
H
D000368:Aged; D000369:Aged, 80 and over; D001661:Biliary Tract Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D002277:Carcinoma / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D017228:Hepatocyte Growth Factor / Q000096:biosynthesis*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D019859:Proto-Oncogene Proteins c-met / Q000096:biosynthesis*; D012008:Recurrence; D016019:Survival Analysis
D017228:Hepatocyte Growth Factor; D019859:Proto-Oncogene Proteins c-met